Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease - Wikidata - wikimedia - TriplyDB

Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease

Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease

http://www.wikidata.org/entity/Q33892744

about

Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases Bridge between neuroimmunity and traumatic brain injury Can nanomedicines kill cancer stem cells?Nanocarriers for vascular delivery of antioxidants Monocyte Trafficking, Engraftment, and Delivery of Nanoparticles and an Exogenous Gene into the Acutely Inflamed Brain Tissue - Evaluations on Monocyte-Based Delivery System for the Central Nervous System Cell delivery of therapeutic nanoparticles GDNF-transfected macrophages produce potent neuroprotective effects in Parkinson's disease mouse model Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins.Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles.Agile delivery of protein therapeutics to CNS Co-opting biology to deliver drugs SOD1 nanozyme salvages ischemic brain by locally protecting cerebral vasculature.Towards nanomedicines for neuroAIDS.Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles.Optimal structural design of mannosylated nanocarriers for macrophage targeting.Cell-mediated drug delivery.Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies Type and composition of surfactants mediating gene transfection of polyethylenimine-coated liposomes.Prolonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages.Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells.Exosomes as drug delivery vehicles for Parkinson's disease therapy Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease.Blood-borne macrophage-neural cell interactions hitchhike on endosome networks for cell-based nanozyme brain delivery.Non-affinity factors modulating vascular targeting of nano- and microcarriers Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells.Exploiting macrophages as targeted carrier to guide nanoparticles into glioma.Nanocarriers for vascular delivery of anti-inflammatory agents Leukocytes as carriers for targeted cancer drug delivery.Lysosomal targeting strategies for design and delivery of bioactive for therapeutic interventions.Indocyanine Green Liposomes for Diagnosis and Therapeutic Monitoring of Cerebral Malaria.Macrophages as Active Nanocarriers for Targeted Early and Adjuvant Cancer Chemotherapy.Neuropharmacologic Approaches to Restore the Brain's Microenvironment.Macrophage-based cell therapies: The long and winding road A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles.Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain.Combining nanoscale magnetic nimodipine liposomes with magnetic resonance image for Parkinson's disease targeting therapy.Monocyte-mediated chemotherapy drug delivery in glioblastoma.Insights on Localized and Systemic Delivery of Redox-Based Therapeutics.

P2860

Q21133553-9599B7A4-AE0C-4D88-BA72-25D646533AC6 Q26827612-45E8F7E2-27ED-4734-BA28-F1DE743F13A7 Q27022017-6B0E0813-9948-42CD-AC64-37218476BB61 Q27027067-1B2BA4DA-E326-4F9F-A9D3-6CF5D2073583 Q27312829-EF9A930A-10C3-4350-9346-F1EE28FCE8C0 Q28385606-46C17F66-7A25-48A3-9EF3-268DD811C811 Q28543023-74727166-077F-4D5D-9F0A-4FD95F0E5F30 Q30387307-ABE32F37-1210-469A-942A-4CDAC6DC6A46 Q33631069-23ABCF1B-0E28-4357-A01D-EBD9E698525A Q34079604-62280A90-CA09-4691-BB63-910BD5348B80 Q34079647-C2D34925-550A-4EBE-8592-34495DB5EFA3 Q34424045-1D04E3A6-3519-4166-9B5B-B543AE917CFD Q34481558-EC1AA8DF-D0CB-4FF0-9EAE-F143F00DE04B Q34495140-A7FE55DE-E6F6-4391-9DBF-9BA6C5EEFEBE Q34566992-6BA88A51-1F0D-4B1C-9358-FB23C1D54339 Q34623115-300D63B8-5CCB-4B0E-A4BC-37FB1B416138 Q34709440-4F2B5EFD-D9A9-40BE-8D4A-239FD29E2F2F Q34797004-DB6766C2-23E6-466F-ADFB-A276262178ED Q35071617-4755B27D-F53B-4FD1-B33C-5A9C8E569D24 Q35153311-C6AF4A81-AFBA-4AC7-9D71-3C2387D1EC07 Q35194750-826FBCBC-C45C-40C4-B0C0-12BC8BFBA33B Q35602589-5A2B42BA-0D3E-46ED-85BF-E94A49B398F7 Q35702733-A97C1078-1079-4306-87C2-21B6827C5D5A Q36063039-EB90164F-4378-4E7A-A8D8-0EB841F43BED Q36703526-AE803E75-B0FC-4057-8042-D5C3C7999029 Q36734451-90D75459-43AC-4C3B-96BA-F3319A1C27E2 Q37392913-5F1F29CA-9608-41A1-AEFD-887E4B849057 Q38176037-B458FEA2-CC30-4191-8A0E-55FD5ADCFF73 Q38255704-048D5004-60EB-40AB-A065-305D917D36F0 Q38634529-CC1A32F1-1792-457F-8537-8CCB0A9D1BE0 Q38794104-19FAB6DD-33ED-4AFE-AE6B-93C23B6DBAD6 Q38827940-49CE43F6-61A8-44F6-AD78-5BCEF8B52398 Q38879533-EF8E9F62-50FA-4287-9542-D2DCE9255BCB Q38898549-0B2850F6-3E1F-491A-9A7E-509ED2430DDF Q39117236-E134745A-2482-4EDB-AEF0-C761950614A2 Q47824357-D263879A-F0D7-4CE2-9406-C8729B74C79F Q48354910-F768ABE5-B237-4976-A680-027FB49050DC Q49664694-CA23C127-8C87-4B3E-9AC4-6FDB9AB1AB6D Q52720174-D096E5D8-5917-4930-980B-6BEB9141869A

P2860

Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease

http://www.wikidata.org/entity/Q33892744

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease

@ast

Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease

@en

type

label

Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease

@ast

Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease

@en

prefLabel

Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease

@ast

Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease

@en

P1433

Q33892744-4D88999E-AD57-4E5E-B767-7179F1236A51

P1476

Q33892744-DDCCC4FB-D920-4A0B-9549-1B01D6637C2B

P2093

Q33892744-35FCF50B-E480-4D27-863B-EE0F2A29A59C

Q33892744-43E3BB6B-E97D-44C1-9C3B-74C0196A7D2D

Q33892744-6C2E9233-A2C9-49BE-BC32-D84B888DFF86

Q33892744-75DC78E9-CB20-4329-AA42-691B6534DDCD

Q33892744-7D461B98-300D-497D-97C0-86A669BD3CCE

Q33892744-9745F4B9-9278-4C1F-BD39-06E8269BDA06

Q33892744-9BA60CF9-2E4A-4689-A74D-ABA27DF92112

Q33892744-A22D214E-9C89-45AF-A618-FFEF8EBC77D9

Q33892744-CF5CB6A4-F680-4191-89C0-94287F406F78

P2860

Q33892744-0A28878B-839D-4501-8A20-F97DCAC409B8

Q33892744-122C35D2-568E-44E5-A26C-5E03B4764FF7

Q33892744-17A985A7-73CC-4B1F-BA84-CD861551373D

Q33892744-1D8F5E88-EB89-4139-92D7-FC87CD87E540

Q33892744-2225400A-4D92-4F53-9363-08486B7C129B

Q33892744-2C05DA5F-A2C8-4AAB-BDA4-AB0DF8AD6EF8

Q33892744-2E120DA6-9773-45EC-9DD1-1EB89BAF42AE

Q33892744-307E8FC7-C126-4C05-A3D8-4088C8EB9E3F

Q33892744-31CCFB5C-B652-46C1-93BB-BAEF151179F3

Q33892744-3440A934-EAB0-449F-A475-72B87BD452A2

P304

Q33892744-9AB278A5-FEE1-4593-BF97-D093086D1512

P31

Q33892744-BCCC8C52-61BC-4664-B62A-53EBB300B850

P356

Q33892744-E2E68F92-9DF2-4717-9FC7-2182BFA942C0

P433

Q33892744-DB250F8B-0301-4A60-8B1B-A32A5DB710DC

P478

Q33892744-328347E3-5DD4-4707-A678-546FD709A1FC

P577

Q33892744-42953AD3-8300-4B05-8E3B-2888D13E091C

P5875

Q33892744-1DD94EF3-7E37-4AE7-9B54-A4EFBDD4FF38

P698

Q33892744-B9E08810-2AC9-4A02-B255-2B8C43CF555A

P921

Q33892744-2BB80AC4-368D-421C-98D7-A9386CA1386A

Q33892744-92C8836D-BF03-4989-98A9-1A2D0CAE6C2F

P932

Q33892744-F4349DA6-770B-49DD-8721-3460EC507345

P356

P1433

P1476

Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease

@en

P2093

Alexander V Kabanov

http://www.w3.org/2001/XMLSchema#string

Anna M Brynskikh

http://www.w3.org/2001/XMLSchema#string

Elena V Batrakova

http://www.w3.org/2001/XMLSchema#string

Howard E Gendelman

http://www.w3.org/2001/XMLSchema#string

Michael D Boska

http://www.w3.org/2001/XMLSchema#string

Natalia L Klyachko

http://www.w3.org/2001/XMLSchema#string

R Lee Mosley

http://www.w3.org/2001/XMLSchema#string

Shu Li

http://www.w3.org/2001/XMLSchema#string

Yuling Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

Parkinson's disease

Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease.

Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.

Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale.

Neurochemical findings in the MPTP model of Parkinson's disease.

Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

4-hydroxynonenal as a bioactive marker of pathophysiological processes.

P304

379-396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/NNM.10.7

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43159076

http://www.w3.org/2001/XMLSchema#string

P698

20394532

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2880389

http://www.w3.org/2001/XMLSchema#string